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Summary
Activated monocytes produce proinflammatory cyto-
kines (monokines) such as interleukin (IL)-12, IL-15,
and IL-18 for induction of interferon-g (IFN-g) by natu-
ral killer (NK) cells. NK cells provide the antiinflamma-
tory cytokine transforming growth factor (TGF)-b, an
autocrine/negative regulator of IFN-g. The ability of
one signaling pathway to prevail over the other is
likely important in controlling IFN-g for the purposes
of infection and autoimmunity, but the molecular
mechanism(s) of how this counterregulation occurs
is unknown. Here we show that in isolated human NK
cells, proinflammatory monokines antagonize antiin-
flammatory TGF-b signaling by downregulating the ex-
pression of the TGF-b type II receptor, and its signal-
ing intermediates SMAD2 and SMAD3. In contrast,
TGF-b utilizes SMAD2, SMAD3, and SMAD4 to sup-
press IFN-g and T-BET, a positive regulator of IFN-g.
Indeed, activated NK cells from Smad32/2 mice pro-
duce more IFN-g in vivo than NK cells from wild-type
mice. Collectively, our data suggest that pro- and anti-
inflammatory cytokine signaling reciprocally antago-
nize each other in an effort to prevail in the regulation
of NK cell IFN-g production.
Introduction
Interferon-g (IFN-g), a cytokine essential for both innate
and adaptive immune responses, is produced princi-
pally by CD4+ and CD8+ T cells, as well as natural killer
(NK) cells. It is critical for successful clearance of intra-
cellular pathogens and also in host defense against
malignant transformation (Dunn et al., 2004; Jouanguy
et al., 1999). Overproduction of IFN-g can lead to auto-
*Correspondence: michael.caligiuri@osumc.eduimmune disorders, such as Crohn’s disease, and
contributes to septic shock, while IFN-g deficiency can
result in a higher susceptibility to infection or malig-
nancy (Bouma and Strober, 2003; Dunn et al., 2002;
Schroder et al., 2004; Shankaran et al., 2001; Trinchieri,
1995). IFN-g production should therefore be subject to
intense positive and negative regulation in cells of the
immune system.
Monocyte-derived proinflammatory cytokines (mono-
kines), such as IL-12, IL-15, and IL-18—especially in
combination—positively regulate IFN-g production
(Cooper et al., 2001; Fehniger et al., 1999). IL-12 is a par-
ticularly potent inducer of IFN-g synthesis in T cells and
NK cells. Its high-affinity receptor is a heterodimer com-
prised of two subunits, the b1 and the b2 chains (Chua
et al., 1994; Presky et al., 1996). IL-12 activates the Ja-
nus kinases Tyk2 and Jak2, leading to phosphorylation
and activation of signal transducer and activator of tran-
scription (STAT)-4 and other STATs as well (Watford
et al., 2004). In addition, IL-12 also activates p38 mito-
gen-activated protein kinase (MAPK) in NK cells and T
cells (Visconti et al., 2000; Zhang and Kaplan, 2000). Im-
portantly, all of these signaling molecules or pathways
activated by IL-12 play a role in positively regulating
IFN-g production (Visconti et al., 2000; Watford et al.,
2004; Zhang and Kaplan, 2000). IL-15 receptors are
comprised of IL-15Ra, IL-2/15Rb, and gc and mainly sig-
nal through Janus kinases (Jak) 1 and 3 and STAT-3
and -5 (McInnes and Gracie, 2004; Ohteki, 2002). IL-18
is a member of the IL-1 family and its receptor is com-
posed of two subunits: the ligand binding subunit,
IL-1Rrp (IL-1 receptor related protein), and the signal
transducing subunit, AcPL (accessory protein-like)
(Akira, 2000; Born et al., 1998). IL-18 signaling is sug-
gested to be mediated by MyD88-NFkB, MAPK, and
STAT-3 (Nakanishi et al., 2001). IL-18 alone is a poor in-
ducer of IFN-g production by naive T cells and NK
cells, due to their weak IL-18R constitutive expression
(Sareneva et al., 2000; Yoshimoto et al., 1998). How-
ever, the combination of IL-12 and IL-18 results in re-
markably synergistic IFN-g production, due in part to
induction of the IL-18R on the cell surface by IL-12
and subsequent reciprocal upregulation of their
receptors (Akira, 2000). The synergistic stimulation of
IFN-g production by IL-12 and IL-18 also results
from the orchestrated action of transcription factors
NFkB, STAT-4, and AP-1, whose binding sites are lo-
cated in the IFNG gene (Akira, 2000; Nakanishi et al.,
2001).
Interestingly, it has been shown that all of the above
proinflammatory cytokines activate transcription of
T-bet, a member of the T-box transcription factor family
(Strengell et al., 2002; Townsend et al., 2004). Glimcher
and colleagues have shown that IFN-g production in
CD4+ T cells, NK cells, and effector CD8+ T cells is con-
trolled by T-bet (Sullivan et al., 2003; Szabo et al., 2002).
Furthermore, T-bet is a master regulator of lineage com-
mitment of TH1 CD4
+ T cells capable of IFN-g production
(Mullen et al., 2001a, 2001b; Szabo et al., 2000, 2002).
T-bet is able to induce itself and two target genes, Hlx1
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576and IL-12Rb2, and to remodel the chromatin structure at
the Ifng locus in T cells (Afkarian et al., 2002; Avni et al.,
2002; Mullen et al., 2001a, 2002). T-bet is also required in
dendritic cells for the optimal production of IFN-g and
optimal activation of antigen-specific TH1 cells (Lugo-
Villarino et al., 2003).
In contrast to proinflammatory cytokines, TGF-b is an
immunosuppressive antiinflammatory cytokine impli-
cated as a negative regulator of IFN-g production by T
and NK cells (Dennler et al., 2002; Letterio and Roberts,
1998). TGF-b is produced by most blood mononuclear
cells, especially NK cells (Horwitz et al., 1997; Letterio
and Roberts, 1998). In most cases, TGF-b signaling is
accomplished via its mediators, SMAD2, SMAD3, and
SMAD4. In the presence of active TGF-b, its type II re-
ceptor (TGF-bRII) transphosphorylates the type I recep-
tor (TGF-bRI) to phosphorylate receptor-regulated
SMADs (R-SMADs), i.e., SMAD2 and SMAD3, which in
turn form heteromeric complexes with a common-part-
ner SMAD (Co-SMAD), i.e., SMAD4 (Shi and Massague,
2003; Wrana et al., 1994). Subsequently, the hetero-
dimers, i.e., SMAD2/SMAD4 and SMAD3/SMAD4, trans-
locate into the nucleus and bind to the promoter regions
of TGF-b-responsive genes (Hata et al., 1997). The N-ter-
minal regions (MH1 domain) in SMAD3 and SMAD4 are
able to bind to DNA directly at the core sequences of
GTCT or AGAC, whereas SMAD2 does not bind directly
to DNA. Promoter bound SMADs can recruit both tran-
scriptional coactivators and transcriptional corepres-
sors (Derynck et al., 1998; Liu et al., 2001; Prunier
et al., 2003; Takeda et al., 2004; Wotton and Massague,
2001), and the balance between the two in the promoter
regions most likely determines whether SMADs activate
or repress the transcription of target genes. TGF-b can
also signal through SMAD-independent pathways such
as p38 MAPK (Bhowmick et al., 2001; Yu et al., 2002).
While it is known that TGF-b suppresses the induction
of IFN-g expression (Bellone et al., 1995; Bright and
Sriram, 1998; Espevik et al., 1987; Pardoux et al., 1999;
Sudarshan et al., 1999) and that this is accomplished
at least in part via inhibition of T-bet (Gorelik et al.,
2002; Lin et al., 2005; Neurath et al., 2002), it is unknown
if this critical negative regulation is dependent or inde-
pendent of the SMAD transcription factor pathway or
if this suppression can occur in a T-bet-independent
fashion.
The interaction of different signaling pathways is
important to provide an integrated response to the cell’s
total signal input. This principle would likely apply to the
monocyte-NK cell innate effector loop after activation by
gram-negative organisms or obligate intracellular path-
ogens where both pro- and antiinflammatory monokines
are released to modulate NK IFN-g production (Reed,
1999). In this study, we investigated the interaction be-
tween pro- and antiinflammatory cytokine signaling
pathways, focusing on their physiological role in regulat-
ing IFN-g production by human NK cells. We demon-
strate that proinflammatory monokines IL-12, IL-15,
IL-18, or their combinations are able to antagonize the
TGF-b signaling pathway in human NK cells by down-
regulating TGF-bRII, SMAD2, and SMAD3. On the other
hand, we found that TGF-b signaling represses mono-
kine-induced IFN-g gene expression and T-BET expres-
sion via SMAD-dependent signaling.Results
Proinflammatory Cytokines Antagonize
Antiinflammatory Cytokine TGF-b Signaling
Monocyte-derived proinflammatory cytokines such as
IL-12, IL-15, IL-18, and their combinations are strong
stimulators of IFN-g production in NK cells through their
activation of transcription factors including STATs,
AP-1, T-BET, and NFkB (Strengell et al., 2002; Townsend
et al., 2004). NK cells constitutively produce TGF-b1 and
can secrete nanogram per milliliter amounts of the latent
form and significant amounts of the active form (Bellone
et al., 1995; Gray et al., 1998; Horwitz et al., 1999). We
therefore asked if the induction of IFN-g gene expres-
sion by these monokines might also simultaneously
benefit from an antagonism of the antiinflammatory
cytokine TGF-b signaling that inhibits IFN-g gene ex-
pression.
Our microarray data indicated that the costimulation
of human NK-92 cells by IL-12 and IL-18 decreased
the mRNA level of TGF-bRII over time (data not shown),
a result we confirmed by real-time RT-PCR and Western
blot analysis (Figure 1A, top, and see Figure S1, top, in
the Supplemental Data available with this article online).
Similar results were obtained in primary human NK cells
when they were purified toR99% and costimulated with
IL-12 and IL-15 or IL-18 (Figure 1A, middle). We also
treated NK-92 cells with IL-12, IL-15, and IL-18 alone
and in combination and noted by real-time RT-PCR
that each of these treatments significantly suppressed
TGF-bRII mRNA expression (Figure 1A, bottom).
We next assessed the TGF-bRII signaling molecule
SMAD2, an R-SMAD. Results from our microarray and
semiquantitative RT-PCR analysis showed that costi-
mulation of NK-92 cells with IL-12 and IL-18 downregu-
lated SMAD2 transcript (data not shown). Western blot-
ting demonstrated that this downregulation also
occurred over time at the protein level (Figure 1B, top).
The inhibition of SMAD2 by the costimulation of IL-12
and IL-18 also occurred in primary NK cells (Figure 1B,
middle). Interestingly, the treatment of NK-92 cells with
IL-12, IL-15, and IL-18 alone and their combinations re-
vealed that only the most potent stimulus of IFN-g
among these proinflammatory cytokine treatments, IL-
12 plus IL-18 (Fehniger et al., 1999), and to a much lesser
degree, IL-15 plus IL-18, downregulated SMAD2 ex-
pression (Figure 1B, bottom, and Figure S1, bottom).
Similar experiments were performed for SMAD3, but
results were distinct from SMAD2 and are summarized
in Figure 1C. A Western blot showed inhibition of
SMAD3 protein expression over time following mono-
kine costimulation in NK-92 (Figure 1C, top), and this de-
crease was confirmed in primary NK cells (Figure 1C,
middle). Further assessment showed that IL-12 or IL-
15 alone, and the costimulation of IL-12 and IL-15 or
IL-18 but not IL-18 alone, inhibited the protein expres-
sion of SMAD3 in NK-92. Monokine costimulation that
normally shows synergy in the induction of IFN-g gene
expression (Cooper et al., 2001; Fehniger et al., 1999)
also showed synergy of SMAD3 inhibition in comparison
to individual cytokines (Figure 1C, bottom). The lack of
SMAD3 inhibition by IL-18 alone is likely due to the
fact that the surface density expression of the IL-18R
in NK-92 cells is weak in the absence of IL-12 stimulation
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577Figure 1. Proinflammatory Cytokines Antagonize Antiinflammatory Cytokine TGF-b Signaling
(A) Top: Protein quantification of TGF-bRII in NK-92 cells by Western blotting. Numbers beneath each lane represent quantification of TGF-bRII
by densitometry, normalized for equivalent loading as determined by b-actin. Middle: Transcript quantification of TGF-bRII in primary NK cells by
real-time RT-PCR relative to the level of the untreated samples that were normalized to 1 (p < 0.01, n = 7). Results from three representative do-
nors are shown. Bottom: Transcript quantification of TGF-bRII as noted above except that NK-92 cells were treated as noted on x axis for 24 hr.
Each condition showed a significantly lower TGF-bRII transcript level compared to the untreated sample that was normalized to 1 (p < 0.01, n = 3).
(B) Protein quantification of SMAD2 by Western blot. Cells and culture conditions are indicated in the figure and Experimental Procedures.
(C) Protein quantification of SMAD3 by Western blot. Cells and culture conditions are indicated in the figure and Experimental Procedures.
(D) Monokine activation reduces NK cell sensitivity to TGF-b1 signaling. NK-92 cells were pretreated with or without monokines for 20 hr, and then
restimulated with the same monokines in the presence or absence of TGF-b1 (10 ng/ml) for 6 hr. The inhibition of IFN-g secretion reflects the NK
cell’s sensitivity to TGF-b1 and was less in the NK cells that received pretreatment with monokines (p < 0.01, n = 3). Error bars in (A) and (D) in-
dicate SD for triplicates in one representative experiment.(Sareneva et al., 2000). Consistent with this, we found
that IL-18 inhibited TGF-bRII expression to a lesser
degree than other proinflammatory cytokines or their
combinations (Figure 1A, bottom). Microarray and semi-
quantitative RT-PCR indicated that the SMAD3 in-
hibition also occurred at the mRNA level (data not
shown).
Interestingly, our microarray and/or Western data
showed that the proinflammatory cytokines we useddid not antagonize SMAD4 or TGF-bRI (data not shown).
To prove that the downregulation of TGF-b signaling
components by monokines is physiologically relevant,
we demonstrated that NK-92 cells pretreated with the
combination of IL-12 and IL-15 or IL-18 showed less
sensitivity to inhibition of IFN-g production by TGF-b1
(Figure 1D). We also found that IL-2 showed effects
equal to those of IL-15 in downregulating TGF-b signal-
ing (Figure S2).
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578Figure 2. Regulation of Human NK Cell T-BET
Expression by Proinflammatory Monokines
and Antiinflammatory TGF-b1
(A) Protein quantification of T-BET expres-
sion via Western blotting. Numbers below
each lane indicate quantification of T-BET
protein under each condition by densitome-
try, normalized for equivalent loading as de-
termined by b-actin.
(B) Quantification of T-BET mRNA by real-
time RT-PCR after 6 hr of culture (p < 0.01,
n = 3). Error bars indicate SD for triplicates
in one representative experiment.
(C) NK-92 cells were treated with or without
TGF-b1 for 24 hr and then stained by immuno-
cytochemistry with an anti-T-BET antibody.
These data are representative of at least three
experiments.The Antiinflammatory Cytokine TGF-b Antagonizes
the Induction of T-BET by Proinflammatory
Cytokines in Human NK Cells
T-bet has been shown to be a master positive regulator
of IFN-g production in murine CD4+ T cells, NK cells,
and CD8+ T cells (Sullivan et al., 2003; Szabo et al.,
2002), but the role of its human homolog, T-BET, in the
regulation of IFN-g in NK cells has not been reported.
We first determined that T-BET is a positive regulator
of human NK cell IFN-g production as well. Dominant-
negative T-BET was overexpressed in the human NK
cell line NK-92, which led to significantly decreased
IFN-g production after costimulation by IL-12 and IL-15
or IL-18 (Figure S3). Further, we found that costimulation
with IL-12 and IL-15 or IL-18 consistently induced T-BET
protein and transcript in NK-92 and in primary human NK
cells (Figures 2A and 2B), consistent with previous data
from the murine system (Gorelik et al., 2002; Neurath
et al., 2002; Szabo et al., 2002; Townsend et al., 2004).In each instance, the T-BET protein levels directly corre-
lated with the levels of IFN-g secretion (data not shown).
TGF-b1 has previously been shown to downregulate
T-bet in murine T cells (Gorelik et al., 2002; Lin et al.,
2005; Neurath et al., 2002). We found that during the
above same set of experiments, the addition of TGF-b1
significantly reduced T-BET protein expression in both
resting and activated NK-92 cells and primary human
NK cells compared to vehicle-treated controls (Fig-
ure 2A). This TGF-b-mediated downregulation of T-BET
was further demonstrated by immunochemical staining
of individual NK-92 cells (Figure 2C) and of primary NK
cells (data not shown). Among the nine normal donors
that we examined, the inhibition of T-BET protein by
TGF-b1 was significant but variable: in resting NK cells,
it was seen in seven of nine donors, and in activated
NK cells in six of nine donors, a result that may in part
be due to a T-BET polymorphism (Akahoshi et al.,
2005). To test whether or not the inhibition of T-BET
Reciprocal Antagonism Regulates NK Cell IFN-g
579Figure 3. Antagonism of T-BET by TGF-b Is Mediated by SMAD Proteins
(A) 293T cells were transfected with the 2 kb T-BET-Luc reporter construct together with various SMAD expression plasmids and their deletion
mutants (D) or the empty vector (PRK5) as indicated. Transfection of each SMAD expression plasmid and their combinations except SMAD2
alone resulted in significantly lower expression of luciferase compared to the PRK5 control plasmid transfection (p < 0.01, n = 3). This effect
was lost upon transfection with each paired D plasmid.
(B) The 2 kb T-BET-Luc promoter construct or its deletions were transfected into 293T cells together with SMAD2 and SMAD4, or DSMAD2 and
DSMAD4, or the empty vector (PRK5), as indicated. Experiments shown here are representative of two performed with similar results.
(C) The2100 bp T-BET-Luc promoter construct was transfected into the DERL-7 NK cell line by electroporation together with SMAD3, SMAD4,
and their combination, or the empty vector (PRK5) as indicated. Transfection of SMAD3, SMAD4, and their combination resulted in significantly
lower expression of luciferase compared to the PRK5 control plasmid transfection (p < 0.01, n = 3).
(D) NK-92 cells were transduced with PINCO-SMAD3 (P-S3) or PINCO (P) only and enriched to 99% purity by FACS (data not shown). Top left:
Verification of SMAD3 overexpression by Western blot. Top right: Quantification of T-BET transcript by real-time RT-PCR. Overexpression of
SMAD3 resulted in significant inhibition of T-BET transcript in both resting and monokine-activated NK-92 cells in the presence of TGF-b1 (10
ng/ml) (p < 0.05, n = 4) but not in the absence of TGF-b1. Bottom: Identical results were obtained for T-BET at the protein level determined by
Western blotting. Numbers below each lane indicate quantification of T-BET protein under each condition by densitometry, normalized for equiv-
alent loading as determined by b-actin. Experiments shown here are representative of three performed with similar results. Error bars in (A)–(D)
indicate SD for triplicates in one representative experiment.expression by TGF-b1 also occurred at the mRNA level,
we assayed the T-BET transcript after TGF-b1 treatment
by real-time RT-PCR. TGF-b1 inhibited T-BET transcript
at baseline and after costimulation by IL-12 and IL-15 or
IL-18 in both NK-92 and primary NK cells with the same
frequency as seen in our protein assay (Figure 2B). We
also assessed the levels of EOMES mRNA, a T-BET-re-
lated transcription factor implicated in IFN-g production
by murine CD8+ T cells (Pearce et al., 2003), but did not
observe any change upon TGF-b1 treatment (data not
shown).
Antagonism of T-BET by TGF-b Is Mediated
by SMAD Proteins
We next investigated the mechanism by which TGF-b1
inhibits T-BET expression. Since TGF-b signaling can
be mediated by both SMAD-dependent and -indepen-
dent pathways (Bhowmick et al., 2001; Yu et al., 2002),
we first tested whether SMAD transcription factors re-
press T-BET gene expression. To this end, we cloned
a 2 kb promoter of human T-BET into the pGL3 luciferasereporter vector. The cloned promoter is 2 kb upstream of
the potential transcription start site determined by the
published mRNA sequence of T-BET in NCBI GenBank
(accession no. NM_013351) and is referred to as the
22 kb promoter. To ensure that this transcription start
site was correct, we used the computer program FirstEF
(Davuluri et al., 2001) to query the genomic sequence
around the T-BET region and found the transcription
initiation region identified by the program to be consis-
tent with the published mRNA sequences in GenBank.
As shown in Figure 3A, the luciferase reporter assays
in 293T cells indicated that transfection with SMAD2
alone, which lacks a DNA binding domain, did not inhibit
T-BET promoter activity. Further, TGF-b1 treatment of
these SMAD2-transfected cells had no effect, likely
due to the very weak intrinsic TGF-b signaling in 293T
cells (data not shown and Y. Chen, personal communi-
cation). However, transfection of SMAD3 and SMAD4
significantly suppressed T-BET promoter activity by
47% and 77%, respectively, in comparison to the empty
vector PRK5 (Figure 3A). Cotransfection of SMAD2
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tic suppression of T-BET promoter activity by 94%
and 96%, respectively. In contrast, none of the SMAD
deletion constructs significantly inhibited constitutive
T-BET promoter activity when transfected into 293T
cells.
To find the minimum T-BET promoter region responsi-
ble for inhibition by SMAD proteins, we performed a
series of deletions of the 2.0 kb T-BET promoter to
make 21.5 kb, 21.0 kb, 2500 bp, 2250 bp, 2100 bp,
and 243 bp promoter reporter constructs. Luciferase
assays indicated that the relative activity of 22.0 kb,
21.5 kb, 21.0 kb, 2500 bp, 2250 bp, 2100 bp, and
243 bp promoters was 37, 28, 29, 26, 23, 21, and 0.8, re-
spectively (Figure 3B). Therefore, the basal activity of
the2100 bp T-BETpromoter was not significantly differ-
ent from the larger promoters with the exception of the
22.0 kb promoter. Moreover, cotransfection of SMAD2
and SMAD4 dramatically repressed the promoter activ-
ity of all six constructs ranging from22.0 kb to2100 bp,
while the activity of the243 bp T-BET promoter was too
low to judge the inhibition (Figure 3B). These data sug-
gested that the T-BET promoter region responsible for
the inhibition by SMAD proteins lies within the 2100 bp
proximal promoter region, and the region from 243 to
2100 may be important for the basal promoter activity.
The luciferase assay was repeated in a human
CD32CD56+ NK cell line called DERL-7 (Di Noto et al.,
2001), confirming that SMAD3 and SMAD4 alone and
in combination were able to repress the activity of
the 2100 bp T-BET promoter (Figure 3C).
To provide further evidence that antagonism of T-BET
by antiinflammatory TGF-b signaling is mediated by
SMAD proteins, we investigated whether or not overex-
pression of SMAD proteins in human NK cells was able
to suppress T-BET expression. Since we showed in
Figure 3A that the overexpression of SMAD3 or
SMAD4 repressed T-BET promoter activity in 293T cells,
we tried to overexpress SMAD3 and SMAD4 in the hu-
man NK-92 cell line by using the GFP-expressing EBV/
retroviral PINCO hybrid vector (Becknell et al., 2005;
Grignani et al., 1998; Trotta et al., 2005). Immunoblotting
indicated substantial overexpression of SMAD3 in the
GFP(+) fraction of cells sorted by FACS (Figure 3D, top
left); however, the overexpression of SMAD4 was un-
successful (data not shown). In the presence of TGF-
b1, both resting and monokine-activated NK-92 cells
overexpressing SMAD3 had significantly less T-BET
transcript and protein than did NK-92 cells overexpress-
ing the vector-GFP control (Figure 3D, top right and bot-
tom). Although overexpression of SMAD3 was also able
to dampen T-BET promoter activity in 293T and DERL-7
cells in the absence of TGF-b1 (Figures 3A and 3C), the
overexpression of SMAD3 in NK-92 cells did not sup-
press T-BET in the absence of TGF-b1 (Figure 3D). This
suggests that for human NK cells, TGF-b1-mediated
suppression of T-BET likely requires more than
SMAD3 (e.g., SMAD3 phosphorylation by TGF-bRI and
dimerization with SMAD4). This notion is consistent
with the observed synergy of T-BET promoter suppres-
sion in 293T cells by combination of SMAD3 and SMAD4
(Figure 3A).
To complement these gain-of-function studies on
T-BET expression, we performed loss-of-functionstudies with NK cells derived from Smad32/2 mice
(Smad22/2 and Smad42/2 mice are embryonic lethal)
(Yang et al., 1999). We analyzed six pairs of Smad32/2
and wt mice and found that NK cells from only three of
sixSmad32/2mice showed an increase of T-bet expres-
sion over wt mice (data not shown), which may be
explained by redundant functions from intact Smad2
and Smad4. These results are consistent with our find-
ings in NK-92 (Figure 3D) and primary human NK cells
(n = 6, data not shown) in that overexpression of
SMAD3 alone, in the absence of TGF-b1, did not consis-
tently inhibit expression ofT-BET expression aftermono-
kine activation.
SMAD Proteins Negatively Regulate IFN-g Gene
Expression in Human and Murine NK Cells
The above results suggest that TGF-b1-mediated activa-
tion of SMAD transcription factors could inhibit IFN-g
production indirectly by targeting T-BET, a master pos-
itive regulator of IFNG. We also tested whether TGF-b1-
mediated activation of SMAD transcription factors could
target IFNG in a direct manner that was independent of
T-BET. We investigated the effect of SMAD expression
plasmids and their deletion mutants on the activity of
an IFNG promoter reporter construct in 293T cells due
to their extremely low T-BET expression (data not
shown). The construct ranges from 23600 to +70 and
also includes 680 bp of intron 1 downstream of lucifer-
ase (Figure 4A, top). As can be seen at the bottom of
Figure 4A, SMAD3 alone and SMAD4 alone significantly
inhibit the activity of the IFNG promoter in 293T cells.
SMAD2 alone again did not show inhibition, likely due
to the lack of a DNA binding domain, yet the cotransfec-
tion of SMAD2 and SMAD4 demonstrated synergy in
suppressing the activity of the IFNG promoter. The
SMAD deletion mutants reversed the suppression. To
determine which region of the IFNG promoter is most re-
sponsible for the inhibition of activity by SMAD proteins,
we performed a promoter mapping analysis. The results
suggested that the most active inhibitory site is likely
within the 2204 proximal promoter region (Figure 4B).
Collectively, these results suggested that TGF-b signal-
ing could target IFNG gene expression in a SMAD-de-
pendent fashion that is independent of T-BET.
Interestingly, SMAD proteins also inhibit the transacti-
vation of the IFNG promoter by T-BET. As shown in
Figure 4C, the introduction of T-BET induced an 8- to
10-fold increase in the promoter activity of IFNG, yet
overexpression of SMAD3 alone or SMAD4 alone but
not SMAD2 was able to significantly inhibit this induc-
tion. Additionally, SMAD2 and SMAD4 or SMAD3 and
SMAD4 produced synergistic inhibition, similar to the in-
hibition of basal T-BET and IFNG promoter activity (Fig-
ures 3A and 4A).
The luciferase assay was repeated in the DERL-7 hu-
man NK cell line, confirming that SMAD3 and SMAD4
alone and in combination were able to repress the activ-
ity of the 2204 bp IFNG promoter (Figure 4D).
To demonstrate that the regulation of both T-BET and
IFNG genes by SMAD-mediated TGF-b signaling is
physiologically important in modulating IFN-g levels in
human NK cells, we investigated whether overexpressed
SMAD3 in primary human NK cells and in the NK-92 cell
line was able to inhibit IFN-g production. Primary NK
Reciprocal Antagonism Regulates NK Cell IFN-g
581Figure 4. SMAD Proteins Inhibit IFNG Promoter Activity in the2204 bp Proximal Region in Both the 293T Cell Line and the DERL-7 NK Cell Line
and Inhibit Transactivation by T-BET
(A) 293T cells were transfected with the 3.6 kb IFNG-Luc reporter construct with intron 1 and either various SMAD expression plasmids, the re-
spective deletion mutants (D), or the empty vector (PRK5), as indicated. Transfection of each SMAD expression plasmid and their combinations
except SMAD2 alone resulted in significantly lower expression of luciferase compared to the PRK5 control plasmid transfection (p < 0.01, n = 3),
which was lost upon transfection with each paired D plasmid.
(B) Full-length and portions of the 3.6 kb T-BET-Luc promoter were transfected into 293T cells together with the empty vector (PRK5), SMAD2
and SMAD4, or DSMAD2 andDSMAD4, as indicated. The y axis indicates relative IFNG promoter luciferase activity. Experiments shown here are
representative of three performed with similar results.
(C) The 3.6 kb T-BET-Luc promoter construct with intron 1 was transfected into 293T cells alone or with various plasmids as indicated. Trans-
fection of each SMAD expression plasmid and their combination except SMAD2 alone resulted in significantly lower expression of luciferase
compared to the T-BET plus PRK5 control plasmid transfection (p < 0.01, n = 3), which was lost upon transfection with each paired D plasmid.
(D) The2204 bp IFNG-Lucpromoter construct was transfected into the DERL-7 NK cell line by electroporation together with SMAD3, SMAD4, and
their combination or the PRK5 control plasmid as indicated. Transfection of SMAD3, SMAD4, and their combination resulted in significantly lower
expression of luciferase compared to PRK5 (p < 0.01, n = 3). Error bars in (A)–(D) indicate SD for triplicates in one representative experiment.cells were first infected by PINCO-SMAD3 retrovirus or
PINCO alone, enriched for purity by FACS (Figure 5A),
and confirmed to overexpress SMAD3 (Figure 5B). We
showed that PINCO-SMAD3-infected cells produce
less IFN-g when stimulated by IL-12 and IL-18 in the ab-
sence or presence of TGF-b1 compared to controls
(Figure 5C). The same results were obtained with NK-
92 cells, where we were able to assess both IFN-g pro-
tein and transcript (Figures 5D and 5E). In contrast to
the results from assessing T-BET expression in NK-92
cells overexpressing SMAD3 (Figure 3D), monokine-in-
duced IFN-g expression was repeatedly inhibited in
the absence of TGF-b1, consistent with the notion put
forth earlier that IFN-g may be suppressed via SMADs
in a direct manner that is independent of T-BET. The en-
hanced inhibition in the presence of TGF-b1 suggests
that additional TGF-b1-activated signaling components
are required for SMAD3 to achieve optimal inhibition. In-
deed, we found that levels of overexpressed SMAD3 in-
creased in the nucleus and decreased in the cytoplasmin a time course that was dependent upon treatment
with TGF-b1 (data not shown).
Finally, we undertook a loss-of-function approach to
address the effects of SMAD proteins on IFN-g gene ex-
pression, utilizing NK cells from Smad32/2mice. We an-
alyzed IFN-gproduction by using NK cells obtained from
seven pairs ofSmad32/2 and wt mice, and we found that
in all instances, monokine-costimulated Smad32/2 NK
cells showed a significantly greater increase of IFN-g
protein production compared to wt NK cells, in both
the absence and presence of TGF-b1 (Figure 5F). Similar
results were quantified at the level of the IFN-g transcript
(data not shown). Likewise,Smad32/2NK cells show less
sensitivity to TGFb1-mediated inhibition of IFN-g gene
expression when compared to wt NK cells (Figure 5G).
These mouse loss-of-function data are consistent with
the gain-of-function data in monokine-activated primary
human NK cells and NK-92 (Figures 5C–5E) in that over-
expression of SMAD3 alone, in both the absence and
presence of TGF-b1, inhibits expression of IFN-g.
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(A) Primary NK cells were retrovirally infected with the PINCO vector or PINCO-SMAD3 and enriched by FACS.
(B) SMAD3 was quantified by real-time RT-PCR in each donor.
(C) The NK cells were costimulated with IL-12 and IL-18 in the presence or absence of TGF-b1 (10 ng/ml) and assayed for IFN-g by ELISA. Results
are representative of at least three donors and show that overexpression of SMAD3 results in significant inhibition of IFN-g (p < 0.05).
(D and E) NK-92 cells were infected as above, enriched by FACS, and costimulated with IL-12 and IL-15 or IL-18 in the presence or absence of
TGF-b1 (10 ng/ml) for 6 hr and assayed for IFN-g secretion (D) by ELISA or IFN-g transcript (E) by real-time RT-PCR. All experiments from (D) and
(E) use nonstarved cells and show a statistically significant difference between the control and SMAD3-infected cells (p < 0.01, n = 3).
(F) NK cells were isolated from spleens of Smad32/2 and wild-type (wt) mice, costimulated for 24 hr in vitro with rmIL-12 and rmIL-15 or rmIL-18,
and assayed for IFN-g secretion by ELISA. NK cells from Smad32/2 mice produce significantly more IFN-g than NK cells from wt mice (p < 0.05,
n = 7 pairs).
(G) Smad32/2 NK cells are significantly less sensitive to TGF-b1-mediated IFN-g inhibition compared to wt NK cells (p < 0.05, n = 7). Error bars in
(B)–(F) indicate SD for triplicates in one representative experiment and in (G) represent SE for three independent experiments.Direct Association of SMAD Proteins on the Human
IFNG Promoter in NK Cells
The gain-of-function and loss-of-function studies
above suggested that SMAD3 might directly regulate
IFN-g expression, and our earlier work (Figure 4B) sug-
gested that a direct binding site could be located in
the 2138 to 2204 region of the IFNG promoter. Exam-
ination of the sequence revealed three potential SMAD
binding sites (GTCT) in this proximal region, each with
a high degree of conservation between human and
mouse (Figure 6A). Two of the three binding sites are
adjacent to each other. We performed EMSAs and
found that a single band formed when using a digoxige-
nin-labeled oligonucleotide containing the two adjacent
SMAD binding sites or the third site with nuclear extract
of NK-92 cells overexpressing SMAD3 (Figure 6B and
data not shown). The 50X or 125X unlabeled identical
oligonucleotide successfully competed with the labeled
sequence for SMAD binding, and a mutated oligonucle-
otide resulted in a substantial decrease of SMAD bind-ing. The addition of anti-SMAD3 antibody to the binding
reaction produced a gel supershift. We next performed
ChIP assays of both endogenous and overexpressed
SMAD3 in NK-92 cells and found that SMAD3 was en-
riched on the IFNG promoter in both cases (Figure 6C
and data not shown). Finally, we found that inhibition
of IFN-g by TGF-b1 or by overexpressed SMAD3 did not
require de novo protein synthesis (Figure S4). These
data support our hypothesis that SMAD proteins (at
least SMAD3) directly bind to and act at the SMAD
binding sites located in the 2138 to 2204 IFNG pro-
moter, consistent with our luciferase assay results.
NK Cells from Smad32/2 Mice Produce More IFN-g
in the Generalized Shwartzman Reaction than NK
Cells from Wild-Type Mice
We previously showed that proinflammatory cytokine
IL-15 stimulates the generalized Shwartzman reaction
and increases IFN-g production by NK cells in this pro-
cess (Fehniger et al., 2000). However, to our knowledge,
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(A) Partial sequences of the proximal human (top) and mouse (bottom) IFNG promoters are shown. Three potential SMAD binding sites (GTCT)
are shown as upper case. The two oligos containing SMAD binding sites and their mutants (arrows) used for electrophoretic mobility shift assays
(EMSAs) are underlined. Two characterized T-BET binding sites (Cho et al., 2003) are boxed. The numbers indicate the position of nucleotides
(transcription start site is referred to as +1) and the stars indicate the sequence homology between mouse and human.
(B) The labeled oligo containing two adjacent SMAD binding sites (lanes 1–4 and 6–8) or its mutant (lane 5) was incubated with (lanes 2–8) or
without (lane 1) nuclear extract of NK-92 cells overexpressing SMAD3 in the presence (lanes 3 and 4) or absence (lanes 1, 2, and 5–8) of excess
unlabeled competitor oligo. SMAD3 antibody (lanes 6 and 7) or normal IgG antibody (lane 8) was also included in the supershift experiment. The
DNA bound SMAD complex and DNA bound SMAD3-a-SMAD3 supershift complex are marked.
(C) Chromatin immunoprecipitation (ChIP) of endogenous SMAD3 in NK cells showed a significant association of SMAD3 on the proximal2204
IFNG promoter in comparison to normal IgG (p < 0.05, n = 3). The amount of the IFNG promoter DNA recovered from ChIP was detected by real-
time PCR. An equal amount (10 mg) of SMAD3 antibody and normal IgG antibody were used in the experiment. Error bars indicate SE for three
independent experiments.the role of TGF-b signaling, especially the Smad protein
cascade, in this lethal in vivo process is unknown.
Above, we demonstrated that SMAD3 is an important
transcription factor to mediate the antagonism between
pro- and antiinflammatory cytokine signaling and to
suppress IFN-g production, a cytokine that is central
to the lethal generalized Shwartzman reaction (Here-
mans et al., 1989). We therefore analyzed the role of
Smad3 in the generalized Shwartzman reaction. We
found that in vivo, CD32NK1.1+ NK cells from
Smad32/2 mice produce higher IFN-g than NK cells
from wt mice by 2-fold (Figure 7, p < 0.01, n = 3). No
IFN-g was detectable by flow cytometry in NK cells
from PBS-treated mice or in CD3+NK1.12 T cells from
LPS-treated mice (data not shown), suggesting that the
regulation of IFN-g produced by NK cells is critical in
the generalized Shwartzman reaction.
Discussion
The opposing actions of pro- and antiinflammatory cyto-
kines are very important for the maintenance of immunesystem homeostasis, as cytokine imbalance is impli-
cated in the genesis or exacerbation of disease (Anto-
nelli, 1999; Bouma and Strober, 2003; Dunn et al.,
2002; Schroder et al., 2004; Shankaran et al., 2001).
Proinflammatory cytokines are primarily responsible
for initiating an effective defense against pathogens
that require a type 1 immune response for clearance
(Hill and Sarvetnick, 2002; Yoshimura et al., 2003). How-
ever, overproduction of these mediators can be harmful
and is implicated in the pathogenesis of inflammatory
bowel disease and septic shock (Bouma and Strober,
2003; Dinarello, 1997, 2000; Schroder et al., 2004). Insuf-
ficient proinflammatory cytokines can result in immuno-
deficiency associated with increased risk of infectious
disease and cancer (Bouma and Strober, 2003; Shan-
karan et al., 2001). In contrast, antiinflammatory or
type 2 cytokines are critical for elimination of some par-
asitic infections and for temporizing the proinflamma-
tory process (Hill and Sarvetnick, 2002; Yoshimura
et al., 2003). Excessive production of antiinflammatory
cytokines may also result in the inappropriate suppres-
sion of the immune response (Bone, 1996).
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and antiinflammatory cytokines is the monocyte/macro-
phage-NK cell innate effector loop. In this loop, host
invasion by either obligate intracellular pathogens or
gram-negative bacteria activates monocyte/macro-
phages to produce proinflammatory cytokines such as
IL-15, -12, and -18, which quickly activate NK cells.
The monokine-stimulated NK cells in turn promptly pro-
duce IFN-g (Fehniger et al., 1999; Tripp et al., 1993), the
prototypic macrophage-activating cytokine required to
effectively contain the pathogen. IFN-g production by
NK cells is a key amplification step within this signaling
circuit as it further induces monocyte/macrophage pro-
duction of IL-15, IL-12, and IL-18 (Hayes et al., 1998; Ma
et al., 1996; Trinchieri, 2003). Several aspects of this
proinflammatory innate effector loop are poorly under-
stood. It is unknown, for example, if monokine produc-
tion of IL-10 (Tripp et al., 1993) or monokine-induced
NK cell apoptosis (Ross and Caligiuri, 1997) are the
only mechanisms preventing uncontrolled amplification
of this positive feedback loop resulting in massive cyto-
kine release. It is also unknown if ‘‘resting’’ NK cells ac-
tively suppress IFN-g production prior to its rapid induc-
tion via proinflammatory cytokine stimulation.
TGF-b is an excellent antiinflammatory cytokine can-
didate to mediate suppression of NK cell IFN-g produc-
tion (Bellone et al., 1995; Bright and Sriram, 1998; Espe-
vik et al., 1987; Pardoux et al., 1999; Sudarshan et al.,
Figure 7. NK Cells from Smad32/2 Mice Produce More IFN-g in the
Generalized Shwartzman Reaction than NK Cells from Wild-Type
Mice
Splenocytes processed from LPS-primed and -challenged mice
were treated with GolgiPlus (2 ml/ml) and LPS (10 mg/ml) for 4–6 hr,
followed by surface staining with CD3-FITC and NK1.1-APC anti-
bodies and subsequent intracellular staining with rat anti-mouse
IFN-g-PE or rat IgG1 Isotype-PE antibodies. The NK cell population
gated on CD32NK1.1+ was analyzed for IFN-g production for both
IFN-g-PE staining (solid line, open) and IgG1 isotype control (shaded
region). NK cells from Smad32/2 mice produced higher IFN-g than
NK cells from wt mice by 2-fold (p < 0.01, n = 3). Results shown rep-
resent one of three pairs of littermate mice.1999). TGF-b1 is produced by every leukocyte lineage,
including NK cells, macrophages, and dendritic cells
(Horwitz et al., 1997; Letterio and Roberts, 1998). Fur-
thermore, NK cells appear to be the only lymphocyte
population that constitutively produces TGF-b1, with
the ability to secrete nanogram per milliliter amounts
of the latent form and significant amounts of the active
form (Bellone et al., 1995; Gray et al., 1998; Horwitz
et al., 1999). Consistent with this notion, we found
that resting human NK cells show constitutive expres-
sion of TGF-bRII, SMAD2, SMAD3, and SMAD4. Collec-
tively, we hypothesize that resting NK cells have a dy-
namic TGF-b-TGF-bR autocrine loop constitutively
active in the absence of proinflammatory immune stim-
ulation. Validation of this signaling loop is currently
underway.
In this study we investigate the hypothesis that, after
activation by proinflammatory monokines, the TGF-
b signaling pathway in human NK cells is disabled. We
show that IL-12, IL-15, and IL-18 individually and/or in
combination are able to antagonize several components
of the TGF-b signaling pathway in NK cells at the mRNA
and protein levels, including its receptor TGF-bRII and
R-SMADs, SMAD2 and SMAD3. While costimulation
with IL-12 and either IL-15 or IL-18 shows synergistic in-
hibition of SMAD3, only the combination of IL-18 and IL-
12 or IL-15 results in downregulation of SMAD2. The an-
tagonism of TGF-b signaling by these proinflammatory
monokines reveals, to our knowledge, a new mecha-
nism by which IFN-g production may be maximized dur-
ing the early innate immune response to infection or ma-
lignant transformation. Taken together, our results
suggest that proinflammatory monokines stimulate ro-
bust IFN-g production in NK cells by downregulating
multiple components of the inhibitory TGF-b signaling
pathway, in addition to upregulating transcriptional acti-
vators of IFN-g production such as STAT and T-BET
proteins.
It had previously been shown that IFN-g itself is able
to antagonize TGF-b signaling in human monocytes (Ul-
loa et al., 1999), but through a mechanism that is distinct
from what is described here for human NK cells re-
sponding to proinflammatory monokines. In the U937
monocytic leukemia cell line, IFN-gwas shown to antag-
onize TGF-b signaling by a Jak1/STAT-1-mediated in-
duction of SMAD7, an antagonistic SMAD, which in
turn prevents the interaction of TGF-bRI with SMAD3
(Ulloa et al., 1999). In a wound model and compared to
wt mice, IFN-g2/2 mice demonstrated enhanced pro-
duction of TGF-b1 and phosphorylated SMAD2 and de-
creased levels of SMAD7 (Ishida et al., 2004). It is not
surprising that the mechanism of IFN-g-induced sup-
pression of the TGF-b signaling pathway is distinct
from the pathway we describe here for monokine-in-
duced suppression in NK cells. The human NK cell line
NK-92 is only weakly responsive to IFN-g (H.A. Young,
personal communication) and IFN-g-stimulated NK-92
cells do not increase STAT-1 phosphorylation (data
not shown). Indeed, stimulation of NK-92 cells with IL-
12, IL-15, or IL-18 and their combinations does not upre-
gulate SMAD7 protein expression (data not shown).
TGF-b exerts a profound influence on dampening NK
cell effector function and is likely the best candidate cy-
tokine for returning and maintaining activated NK cells
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585to their resting state, at least in part by inhibiting IFN-g
production. Although the phenomenon of TGF-b-medi-
ated suppression of IFN-g production has been widely
reported (Bellone et al., 1995; Bright and Sriram, 1998;
Espevik et al., 1987; Pardoux et al., 1999; Sudarshan
et al., 1999), the mechanisms by which this occurs are
not fully elucidated. One mechanism that is clear in mu-
rine T cells is the downregulation of T-bet (Gorelik et al.,
2002; Lin et al., 2005; Neurath et al., 2002), something we
confirm here in human NK cells.
It has also been postulated that TGF-b interferes with
early signaling events activated by proinflammatory cy-
tokines, i.e., TGF-b might antagonize the activation of
JAKs or STATs. However, there are conflicting reports
on this possibility. Two independent groups showed
that in human T cells TGF-b1 inhibits IL-12-induced
phosphorylation of JAK2, TYK2, and STAT4 (Bright
and Sriram, 1998; Pardoux et al., 1999). In contrast, Su-
darshan et al. reported that, in primary T cells and the
NK3.3 cell line, TGF-b1 had no effect on IL-12-induced
phosphorylation of JAK2, TYK2, or STAT4, although it
did inhibit IL-12-induced IFN-g production (Sudarshan
et al., 1999). There are also conflicting reports for the in-
hibitory effects of TGF-b on IL-2-induced activation of
JAK and STAT proteins (Bright et al., 1997; Han et al.,
1997; Sudarshan et al., 1999). These results suggested
to us that TGF-b may inhibit NK cell IFN-g production
by alternative mechanisms.
In the current study, we provide new data demonstrat-
ing that TGF-b downregulates T-BET, the positive regu-
lator of IFN-g, via SMAD2, SMAD3, and SMAD4. We also
show that these same SMAD proteins can decrease T-
BET-mediated transactivation of the IFNG promoter to
less than basal level (Figure 4C), suggesting that the
suppression of IFN-g expression by the SMAD proteins
is able to override the activation by T-BET likely in part
via negative regulation of IFN-g that is independent of
SMADs’ direct effect on T-BET.
It is unclear how these SMAD transcription factors are
able to inhibit T-BET transactivation of IFN-g. There may
be a convergence of these factors at a common location
within the IFNG promoter. In support of this, we found
that there is an enriched region for SMAD and T-BET
binding sites at the proximal promoter of IFNG from
258 to 2217. In this region, there are at least four
GTCT/AGAC SMAD binding sites and two previously
characterized T-BET binding sites (Cho et al., 2003),
suggesting that these transcription factors may interfere
with each other at this region. We were able to show the
direct binding of the SMAD3 protein to specific sites
within the human IFNG proximal promoter as well as
SMAD-mediated suppression of the IFNG promoter ac-
tivity by luciferase assays in both 293T cells and the
DERL-7 NK cell line. Our preliminary data also indicate
the direct binding of T-BET to the human IFNG proximal
promoter (data not shown). By coimmunoprecipitation,
we could not detect a significant interaction between
SMAD3 and T-BET, suggesting that they bind to this
proximal promoter region independently.
We found that negative regulation of IFN-g by TGF-
b can be independent of SMAD-mediated T-BET inhibi-
tion. We noted that, in the absence of TGF-b1, overex-
pression of SMAD3 in NK-92 cells led to a significant
decrease of IFN-g production after monokine activationwithout a concomitant T-BET decrease (see Figures 3D,
5D, and 5E and data not shown). Additionally, we
showed that monokine-stimulated Smad32/2 NK cells
consistently express more IFN-g than NK cells from wt
mice (Figure 5F), while expression of T-bet under identi-
cal conditions was highly variable and showed no signif-
icant difference (data not shown). Finally, monokine-
stimulated NK-92 cells expressing a dominant-negative
T-BET also exhibited significant inhibition of IFN-g by
TGF-b1 (data not shown). It will be interesting to see
if TGF-b1 is able to downregulate IFN-g production in
T-bet2/2 mice. These results suggest that TGF-b may
inhibit other transcription factors as well, such as AP1,
NF-kB, and STATs. However, our lab and other groups
have found that IFN-g production cannot be completely
suppressed by TGF-b, suggesting that cooperation with
other cytokine pathways is likely.
Our reproduction of the generalized Shwartzman
reaction provides in vivo evidence that the TGF-b signal-
ing mediator Smad3 can suppress IFN-g production.
We found that NK cells of Smad32/2 mice produce
2-fold higher IFN-g than wt mice. This finding may prove
useful in either explaining excessive immune activation
involving IFN-g in illnesses such as inflammatory bowel
disease or in partially blocking the effects of excess
TGF-b in vivo.
Our data also provide the molecular basis for the ear-
lier observations that blocking endogenous TGF-b in
fresh human endometrial cell cultures increases the pro-
duction of IFN-g by uterine NK cells (Eriksson et al.,
2004), and blockade of TGF-b signaling in mice results
in the accumulation of a large pool of NK cells secreting
copious IFN-g responsible for TH1 differentiation and
Figure 8. A Model of Reciprocal Antagonism between Proinflamma-
tory and Antiinflammatory Cytokine Signaling Pathways in Regulat-
ing IFN-g Production
The model is suggested by our results presented here and by previ-
ously published studies (Gorelik et al., 2002; Neurath et al., 2002;
Szabo et al., 2002; Townsend et al., 2004). Proinflammatory cyto-
kines, such as IL-12, IL-15, and IL-18 alone and especially in combi-
nation, induce the expression of T-BET, a positive, direct regulator of
IFN-g gene expression. They also inhibit the expression of TGF-b
type II receptor (TGF-bRII), SMAD2, and SMAD3. TGF-b signaling
inhibits IFN-g gene expression via SMAD proteins in a manner that
is both T-BET dependent and independent.
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Thus, we hypothesize that the ‘‘resting state’’ for human
NK cells likely consists of active antiinflammatory cyto-
kine signaling that results in suppression of proinflam-
matory immune activation.
In summary, we provide new mechanistic data dem-
onstrating reciprocal antagonism between pro- and
antiinflammatory cytokine signaling pathways operating
in human NK cells (Figure 8). We show that monokines
IL-12, IL-15, and IL-18 act alone and/or in combination
to antagonize TGF-b signaling via downregulation of
TGF-bRII and its signaling mediators, SMAD2 and
SMAD3. We show that TGF-b utilizes SMAD2, SMAD3,
and SMAD4 to antagonize IFN-g gene expression via
suppression of T-BET and also via a direct, T-BET-inde-
pendent negative regulatory effect on the IFNG pro-
moter. Given the role that IFN-g has in promoting im-
mune editing of tumors (Dunn et al., 2002; Shankaran
et al., 2001) and TGF-b’s role in promoting late-stage on-
cogenesis via immune suppression (Bellone et al., 1995;
Castriconi et al., 2003; Lee et al., 2004), developing a tar-
geted strategy to modulate SMAD gene expression may
add a useful and novel component to the treatment of
malignant disease.
Experimental Procedures
Cell Culture and Isolation of Primary NK Cells
The human IL-2-dependent NK cell line NK-92, a generous gift of
Dr. Hans G. Klingemann (Rush University Medical Center, Chicago,
IL) (Gong et al., 1994), and DERL-7, a kind gift of Drs. Rosella Di
Noto (Universita` Federico II, Naples, Italy) and Francesco Salvatore
(The CEINGE Bank of Human and Animal Continuous Cell Lines, Na-
poli, Italy) (Di Noto et al., 2001), were maintained in culture in RPMI-
1640 medium (Invitrogen, Carlbad, CA) containing Glutamax, sup-
plemented with 20% heat-inactivated FBS (Invitrogen), and 150 IU/
ml rhIL-2 (Hoffman-LaRoche Inc., Nutley, NJ) at 37ºC. The ampho-
tropic-packaging cell line Phoenix (gift from Dr. Garry P. Nolan, Stan-
ford University, CA) was maintained in culture in Dulbecco modified
Eagle medium (DMEM) (Invitrogen)/10% FBS medium and grown for
16 to 18 hr to 80% confluence prior to transfection by calcium phos-
phate-DNA precipitation (Promega, Madison, WI). Human primary
NK cells were isolated from peripheral blood leukopacks of healthy
donors (American Red Cross, Columbus, OH) by incubation for
30 min with RossetteSep cocktail (StemCell Technologies Inc., Van-
couver, Canada), followed by Ficoll-Hypaque density gradient
centrifugation, and by plastic adherence overnight to remove the
monocyte population. Enriched NK cells were w80% CD56+, as
determined by fluorescence activated cell sorter (FACS) analysis
with an anti-CD56 phycoerythrin (PE)-conjugated monoclonal anti-
body (Immunotech, Marseille Cedex 9, France). The enriched NK
cells were directly used for retroviral infection and infected cells
were then purified by FACS (see below). For all other experiments,
enriched NK cells were further enriched to R99% CD56+CD32 by
cell sorting or by using CD56 MicroBeads and MACS LS Separation
Columns (Miltenyi Biotec, Auburn, CA). NK cells from splenocytes
of Smad32/2 and wild-type (wt) C57BL/6 or A/J strain mice (8 to
15 weeks old) were enriched to 70%–80% by DX5-PE/NK1.1-PE
antibodies and PE Microbeads by LS Separation Columns and
were further purified toR99% DX5/NK1.1+CD32 by cell sorting.
Plasmid Construction
The 2.0 kb (21 to 22000) sequence of the T-BET gene promoter
was generated by PCR from human genomic DNA, and the promoter
sequences of 1.5 kb (21 to21500), 1.0 kb (21 to21000), 500 bp (21
to2500), 250 bp (21 to2250), and 100 bp (21 to2100) were ampli-
fied from a plasmid containing the 2.0 kb fragment. The upstream
primers for the application of these sequences were: T-BET-
2KbXho, 50-ACTCGAGAGCCAAGCACTGAGCAAAAATGT-30; T-BET-1.5KbXho, 50-ACTCGAGCAGAAATGTAGAGCTGGGGC-30; T-BET-
1.0KbXho, 50-ACTCGAGATCTCCGAGGCAGCCCTTCA-30; T-BET-
500bpXho, 50-ACTCGAGGGAGAAAGAGGGCAACCCGA-30; T-
BET-250bpXho 50-ACTCGAGCTTCAAAGCTGGGCTGAATT-30;
T-BET-100bpXho, 50-ACTCGAGGGCGGGGTGGGGCGAGGCGG-30.
The downstream primer was T-BETPrtHindIII 50-TAAAGCTT CTGT
CACTAGAGTCGCAGCGCTTT-30. The amplified promoter fragments
were cloned into the PCR2.1 vector (Invitrogen) and the sequences
were confirmed by DNA sequencing. The sequenced fragments
then were digested from the PCR2.1 vector by XhoI and HindIII and
cloned into the same restriction sites of the pGL3 luciferase basic re-
porter vector (Promega) to generate T-BET-LUC reporter constructs.
The 243 bp T-BET promoter construct was made by ligating the
XhoI-HindIII pGL3 fragment with two annealed oligos: -43T-
BETXho1Up, 50-TCGAAGCTTCATAAAGCCACAGCAAAGCGCTGC
GACTCTAGTGACAG-30 and -43T-BETHindDN, 50-AGCTCTGTCAC
TAGAGTCGCAGCGCTTTGCTGTGGCTTTATGAAGCT-30. A series
of IFNG promoter constructs with different lengths were kind gifts
from Dr. Howard A. Young and Dr. Jay Bream (National Cancer Insti-
tute, National Institutes of Health, Frederick, MD) or Dr. Rivkah Gon-
sky (Cedars-Sinai, Los Angeles, CA).
Dominant-negative T-BET (dnT-BET) is a chimeric fusion of the
human T-BET N terminus (amino acids 1–371, accession number
NP_037483) with the Drosophila Engrailed repression domain
(amino acids 2–298, accession number XP_080792). The T-BET por-
tion was obtained by RT-PCR from human peripheral blood mono-
nuclear cell cDNA. The Engrailed portion was obtained by RT-PCR
fromDrosophila embryo cDNA (Clontech, Palo Alto, CA). The chime-
ric cDNA was cloned in a quaternary ligation reaction consisting of
BglII-SphI T-BET, SphI-BsrBI T-BET, SfoI-XhoI Engrailed, and
BglII-XhoI pCMV-HA (Clontech). This cDNA was sequenced bidirec-
tionally and subcloned to the BamHI-EcoRI sites of PINCO retroviral
vector (Becknell et al., 2005; Grignani et al., 1998; Trotta et al., 2005),
after blunting the XhoI and EcoRI sites with Klenow fragment. A C-
terminal MYC epitope was subsequently added to permit detection
of the dnT-BET protein. Alternatively, as a negative control, the En-
grailed repression domain was amplified along with a start codon
and a C-terminal MYC tag and ligated into pCR2.1 (Invitrogen). After
sequencing, this cDNA was subcloned to the BamHI-EcoRI sites of
PINCO retroviral vector. The PINCO retroviral vector was kindly pro-
vided by Dr. Martin Sattler (Dana-Farber Cancer Institute, Harvard
University, Boston, MA).
SMAD2, SMAD3, and SMAD4 expression plasmids on the PRK5
vector, their deletion mutants, and the empty vector PRK5 for clon-
ing SMAD genes have been previously described (Zhang et al., 1996,
1998) and were kind gifts from Dr. Rik Derynck (University of Califor-
nia at San Francisco, San Francisco, CA). We reamplified SMAD3
from the PRK5 backbone by PCR and the amplified fragment with
a BamH1 restriction site before the start codon and an EcoR1 re-
striction site after the stop codon was cloned into the PCR2.1 vector
(Invitrogen). The sequenced SMAD3 from PCR2.1 was subcloned
into BamHI-EcoRI sites of PINCO to create PINCO-SMAD3.
Luciferase Reporter Assays
293T cells were seeded into 24-well plates at a concentration of 2.53
105 per well and grown overnight. The T-BET-Luc or the IFNG-Luc
construct (1mg) and various SMAD expression plasmids or the empty
vector PRK5 (1 mg each) were cotransfected into 293T cells by Lipo-
fectamine 2000 with Plus Reagent (Invitrogen) according to the man-
ufacturer’s protocol. The pGL3 basic reporter vector was used as
a control for basal-promoter activity. A renilla-luciferase vector (5
ng), pRL-TK (Promega), was cotransfected to serve as an internal
control for transfection efficiency. Cells were harvested after 48 hr
of transfection and assessed for luciferase activity by the dual lucif-
erase reporter assay system (Promega). To transfect the DERL-7 NK
cell line, the promoter and/or expression constructs (5 mg each) and
pRL-TK (50 ng) were electroporated into 4.0 3106 cells by Cell Line
Nucleofector Kit V and an Amaxa electroporator (Amaxa, Inc, Gai-
thersburg, MD) according to the manufacturer’s protocol. Cells
were harvested after 20 hr of transfection and assessed for luciferase
activity by the dual luciferase reporter assay system. Total amounts
of transfected DNA were adjusted to be the same using the empty
vector in all assays of each experiment. All assays were done in trip-
licate and all values were normalized for transfection efficiency
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pRL-TK plasmid. The activity of the pGL3 basic reporter vector alone
(always between 1/10 and 1/5 of experimental values) was sub-
tracted from that of the vector with a promoter, and the mean 6 SD
of the triplicate values of the difference is shown in the figures.
NK Cell Stimulation and IFN-g Immunoassay by ELISA
IL-2-dependent NK-92 cells, starved forw24 hr unless otherwise in-
dicated, or purified human primary NK cells were treated with or
without varied cytokines, IL-12, IL-15, IL-18, and TGF-b1 (R & D Sys-
tems, Minneapolis, MN), for 24 hr or the indicated time. Cells were
harvested to extract RNA for synthesizing cDNA or to extract pro-
teins for Western blotting. Cell-free supernatants were collected
for detecting IFN-g protein by enzyme-linked immunosorbent assay
(ELISA) with commercially available mAb pairs (Endogen Inc., Wo-
burn, MA) according to the manufacturer’s protocol. Murine NK
cell stimulation and ELISA were performed similarly except that mu-
rine monkines and antibodies (R & D Systems) were used. Results
are shown as a mean of triplicate wells 6 SD. Recombinant human
IL-12 (rhIL-12) and murine IL-12 (rmIL-12) were kindly provided by
the Genetics Institute Inc. (Cambridge, MA), rhIL-18 and rmIL-18
by BASF Bioresearch Corporation (Worcester, MA), and rhIL-15
and rmIL-15 by Amgen (Thousand Oaks, CA). Unless specified, the
concentration used for rhIL-12 was 10 ng/ml, rhIL-15 100 ng/ml,
rhIL-18 100 ng/ml, rmIL-12 20 ng/ml, rmIL-15 20 ng/ml, rmIL-18 10
ng/ml, and TGF-b1 20 ng/ml.
Retroviral Infection of the NK-92 Cell Line and Primary Human
NK Cells
For infection, the NK-92 cell line and enriched primary human NK
cells were pretreated with 900 IU/ml IL-2 for 1 or 2 days and infected
in the presence of 900 IU/ml IL-2. Retroviral infections were per-
formed by utilizing a hybrid EBV-retroviral vector following previ-
ously published protocols (Becknell et al., 2005; Grignani et al.,
1998; Trotta et al., 2005). In brief, infectious supernatants from
PINCO and PINCO-SMAD3 transiently transfected Phoenix cells
were collected 48 hr after transfection and used for three cycles of
infections. Upon infection, NK-92 cells were sorted (FACS Vantage;
BD Biosciences, San Jose, CA) for green fluorescent protein (GFP)
expression, and primary NK cells were sorted for GFP and CD56 ex-
pression upon staining with an anti-CD56 allophycocyanin (APC)-
conjugated monoclonal Ab (Immunotech). GFP+CD56+ primary NK
cells were used immediately after sorting. Overexpression of
SMAD3 was confirmed in NK-92 cells by Western blotting and in pri-
mary NK cells by real-time RT-PCR (see below).
Cell Lysis and Immunoblotting
Cells were harvested, washed once with ice-cold PBS, and lysed
(108 cells/ml lysis buffer) in hypertonic buffer (1% NP-40, 10 mM
HEPES [pH 7.5], 0.5 M NaCl, 10% glycerol supplemented with prote-
ase and phosphatase inhibitors [1 mM phenylmethylsulfonylfluoride
(PMSF), 1 mM Na3VO4, 50 mM NaF, 10 mM b-glycerol-phosphate, 1
mM EDTA, and protease inhibitor cocktail tablet (Roche Applied Sci-
ence, Indianapolis, IN)]). Alternatively, for direct lysis, 3 3 105 cells
were washed once with ice-cold PBS and directly lysed in 30 ml of
Laemmli buffer. Lysates were electrophoretically separated on
4%–15% gradient SDS-PAGE gels (Bio-Rad Lab, Hercules, CA)
and were transferred to nitrocellulose membranes. The membranes
were blocked with 5% milk in TBS-0.1% Tween 20. The primary an-
tibody was usually diluted 1:1000 with 5% milk in TBS-0.1% Tween
20 and was added to react with the membrane overnight. The mem-
brane was then washed three times in TBS-0.1% Tween 20. The HRP
bound secondary antibody (Amersham Corp., Arlington Heights, IL)
was diluted 1:5000 with 5% milk in TBS-0.1% Tween 20 and was
added to the membrane to stand for 1 hr. The membrane was again
washed four times in TBS-0.1% Tween 20 and an enhanced chem-
iluminescence (ECL; Amersham Corp.) was added for 1 min. The
blot was then exposed to film for various lengths of time. The b-actin
Western was included as a control to demonstrate equal loading.
Antibodies used were: mouse monoclonal anti-T-BET (Santa Cruz
Biotechnology, Santa Cruz, CA); rabbit polyclonal anti-SMAD2 (Cell
Signaling Technology, Beverly, MA); rabbit polyclonal anti-human
TGF-b type II receptor (Upstate Biotechnology, Lake Placid, NY);
rabbit polyclonal anti-SMAD3 (Zymed Laboratory Inc, South SanFrancisco, CA); mouse Myc-tag monoclonal antibody (Cell Signaling
Technology), and goat polyclonal anti-b-actin (Santa Cruz Biotech-
nology).
Immunocytochemistry of T-BET
NK-92 cells or primary human NK cells were treated with or without
TGF-b1 for 24 hr and fixed with 4% paraformaldehyde for 20 min.
Slides were prepared by depositing 3 3 105 cells onto glass slides
with the use of a Cytospin 3 centrifuge (Thermo Shandon, Pitts-
burgh, PA). Cells were permeabilized for 5 min at room temperature
with 0.2% Triton X-100, and then blocked with blocking buffer (10%
normal goat serum in PBS) for 1 hr at room temperature before incu-
bating overnight at 4ºC with anti-mouse T-BET (Santa Cruz Biotech-
nology) diluted 1:8 in blocking buffer. After washing two times in
PBS, the slides were stained with AlexFlour 488-goat-anti-mouse
IgG (Molecular Probes, Eugene, OR) for 1.5 hr, washed, and
mounted with Vectshield Mounting Medium with DAPI (Vector Lab-
oratories, Burlingame, CA). In a parallel control experiment, it was
observed that omission of the primary antibody eliminated staining.
Fluorescence, corresponding to presence of anti-T-BET, was de-
tected by means of a Zeiss LSM 510 microscope equipped with Sap-
phire multiphoton and Argon/HeNe lasers.
Real-Time RT-PCR
Total RNA from NK-92 cells or primary NK cells was isolated with
RNeasy kit (Qiagene, Valencia, CA). cDNA was synthesized from 1–
3 mg total RNA with random hexamers (Invitrogen). Real-time RT-
PCR reactions for the human IFN-g transcript were performed as
a multiplex reaction with the primer/probe set specific for the IFN-g
cDNA (forward primer, 50-GAAAAGCTGACTAATTATTCGGTAACT
G-30; reverse primer, 50-GTTCAGCCATCACTTGGATGAG-30; probe,
50FAM-CTTGAATGTCCAACGCAAAGCAATACATGA-30TAMRA) and
an internal control (18S rRNA, PE Applied Biosystems, Foster City,
CA). The reactions for the human TGF-bRII transcript (forward
primer, 50-TGTCTGTGGATGACCTGGCTAA-30; reverse primer, 50-
TTCTAGGACTTCTGGAGCCATGT-30; probe, 50FAM-AGTGGGCAG
GTGGGAACTGCAAGA-30TAMRA), SMAD2 transcript (forward
primer, 50-CGAAATGCCACGGTAGAAAT-30; reverse primer, 50-
GGCACTCAGCAAAAACTTCC-30; probe, 50FAM-AGGAAGAGGAGT
GCGCTTAT-30TAMRA), and SMAD3 transcript (forward primer, 50-
CCGAATCCGATGTCCCC-30; reverse primer, 50-AAGGCCGGCTCG
CAGT-30; probe, 50FAM-CACATAATAACTTGGACCTGCAGCCAGT
TACC-30TAMRA) were performed similarly. Alternatively, reactions
for the human T-BET transcript (forward primer, 50-CAACAATGT
GACCCAGATGAT-30; reverse primer, 50-AATCTCGGCATTCTGGT
AGG-30; probe, 50FAM-CCGGCTGCATATCGTTGAGGTGAAC-30TA
MRA) were performed separately from the 18S control. cDNA from
phytohemagglutinin (PHA)-activated human lymphocytes served as
positive controls and water without a cDNA template was used as
a negative control. Conditions for real-time RT-PCR were: stage 1,
50ºC 2 min; stage 2, 95ºC 10 min; stage 3, 95ºC 15 s, 60ºC 1 min
with 40 cycles. Real-time RT-PCR reactions were performed with
an ABI prism 7700 sequence detector (Taqman; PE Applied Biosys-
tems), and data were analyzed with the Sequence Detector version
1.6 software to establish the PCR cycle at which the fluorescence
exceeded a set threshold, CT, for each sample. Data were analyzed
according to the comparative CT method, as previously described
(Fehniger et al., 1999), using the internal control (18S) transcript levels
to normalize differences in sample loading and preparation. Results
represent the n-fold difference of transcript levels between different
samples and are expressed as the mean 6 SD of triplicate reaction
wells.
Electrophoretic Mobility Shift Assays
Electrophoretic mobility shift assays (EMSAs) were performed with
the Dig Gel Shift Kit, 2nd Generation (Roche Applied Science) ac-
cording to the manufacturer’s protocol. The digoxigenin-labeled oli-
gos, the unlabeled competitor oligos, and the mutant oligos corre-
sponded to two different putative SMAD3 binding sites within the
proximal IFNG promoter (2138 to 2204). Where indicated, a 50-
fold or a 125-fold molar excess of unlabeled competitor oligo DNA
was used in competition experiments. For antibody supershift, rab-
bit anti-SMAD3 antibody (Zymed Laboratory Inc.) or normal rabbit
IgG antibody (as a control, Upstate Biotechnology) was added to
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a 5% polyacrylamide gel in 13 TBE buffer and were exposed to film.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed with the ChIP
Assay Kit (Upstate Biotechnology) according to the manufacturer’s
protocol. An equal amount (10 mg) of rabbit polyclonal anti-SMAD2/3
(Santa Cruz Biotechnology) and normal rabbit anti-IgG (Upstate Bio-
technology) was used to precipitate a cross-linked DNA/protein
complex. The IFNG primer set and the probe used to detect the
amount of precipitated DNA from the2138 to2204 region were de-
scribed previously (Messi et al., 2003).
IFN-g Production in the Generalized Shwartzman Reaction
Sex-matched littermates of Smad32/2 and wt C57BL/6 mice (18 to
20 weeks old) were subcutaneously injected with 40 mg lipopolysac-
charide (LPS, Sigma, St. Louis, MO) per mouse for priming and after
24 hr were i.v. challenged with 400 mg LPS. After one of the paired
littermates died (usually within 20 hr), another littermate was sacri-
ficed to ensure equal time periods of the LPS treatment. Single-
cell-suspension splenocytes processed from spleens were cultured
in the presence of GolgiPlus (BD Biosciences, 2 ml/ml) and LPS (10
mg/ml) for 4–6 hr to allow IFN-g protein to accumulate in the golgi,
harvested, and stained with CD3-FITC and NK1.1-APC (BD Biosci-
ences) by surface staining and with rat anti-mouse IFN-g-PE and
rat IgG1 Isotype-PE (BD Biosciences) by intracellular staining. The
IFN-g production by CD32NK1.1+ NK cells was determined by flow
cytometry.
Mice
Smad32/2 and wt C57BL/6 or A/J mice were used for comparing
IFN-g or T-BET expression after monokine stimulation in vitro or af-
ter induction of the generalized Shwartzman reaction in vivo. All an-
imal work was approved by The Ohio State University Animal Care
and Use Committee, and mice were treated in accordance with
the institutional guidelines for animal care.
Microarray Analysis
NK-92 cells were cultured in the medium without IL-2 for 24 hr. The
starved cells were costimulated with IL-2 (150 U/ml), IL-12 (10 ng/
ml), and IL-18 (20 ng/ml) for 0 hr, 1 hr, 2 hr, 4 hr, 6 hr, 10 hr, and 12
hr, respectively. The cells were harvested and total RNA was iso-
lated with TriZOL Reagent (Invitrogen) and the RNeasy kit (Qiagene).
Preparation of cRNA, hybridization, and scanning of the human
genes U95A arrays were performed according to the manufacturer’s
protocol (Affymetrix, Santa Clara, CA). The chips of the Human Ge-
nome U95Av2 Array were used and they represent approximately
10,000 full-length genes.
Statistics
Data were compared by Student’s two-tailed t test. p less than 0.05
was considered statistically significant.
Supplemental Data
Supplemental Data include four figures and can be found with this
article online at http://www.immunity.com/cgi/content/full/24/5/
575/DC1/.
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